Finally – Action on Prescribing Through Telehealth

Last week, we finally saw a proposed rule – “Telemedicine Prescribing of Controlled Substances When the Practitioner and the Patient Have not had a Prior In-Person Medical Evaluation” arrive at OMB.  We expect that this proposed rule will avert the current end of telehealth prescribing flexibility on December 31, 2024.  However, there remains significant risk [...]

2024-06-17T16:23:47-04:00June 17th, 2024|

Drug Enforcement Administration Notice of Proposed Rulemaking Summary

Telemedicine prescribing of controlled substances when the practitioner and the patient have not had a prior in-person medical evaluation (RIN: 1117-AB40)Drug Enforcement Administration Notice of Proposed RulemakingPublic comments due March 31, 2023DEA Resources: Rule Text Highlights for Medical PractitionersDEA Summary ChartSee companion buprenorphine rule summary hereProposed Rule OverviewThe Ryan Haight Act of 2008 directed the [...]

2023-03-16T17:43:46-04:00February 27th, 2023|

Summary of Expansion of Induction of Buprenorphine via Telemedicine Encounter

The Drug Enforcement Administration (DEA) released its Notice of Proposed Rulemaking (NPRM) on buprenorphine via telemedicine encounter, a summary, and highlights for medical practitioners. The proposed rule amends the DEA’s regulations, in concert with the Department of Health and Human Services (HHS), on the circumstances under which individual practitioners are authorized to prescribe schedule [...]

2023-03-07T14:11:03-04:00February 27th, 2023|

Longer-Term Effects of Remote Patient Management Following Hospital Discharge After Acute Systolic Heart Failure: The Randomized E-INH Trial

Longer-Term Effects of Remote Patient Management Following Hospital Discharge After Acute Systolic Heart Failure: The Randomized E-INH Trial Background: The randomized INH (Interdisciplinary Network Heart Failure) trial (N = 715) reported that 6 months' remote patient management (RPM) (HeartNetCare-HF) did not reduce the primary outcome (time to all-cause death/rehospitalization) vs usual care (UC) in patients discharged [...]

2023-02-22T15:33:31-04:00January 11th, 2023|

Heart Failure Drug Treatment-Inertia, Titration, and Discontinuation: A Multinational Observational Study (EVOLUTION HF)

Heart Failure Drug Treatment-Inertia, Titration, and Discontinuation: A Multinational Observational Study (EVOLUTION HF) Background: Guidelines recommend early initiation of multiple guideline-directed medical therapies (GDMTs) to reduce mortality/rehospitalization in patients with heart failure and reduced ejection fraction. Understanding GDMT use is critical to improving clinical practice. Objectives: This study sought to describe GDMT use in Japan, Sweden, and [...]

2023-02-22T15:25:09-04:00January 1st, 2023|

Diabetes Technology: Standards of Care in Diabetes—2023

Diabetes Technology: Standards of Care in Diabetes—2023 The American Diabetes Association (ADA) “Standards of Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary [...]

2023-02-22T14:01:16-04:00December 12th, 2022|

Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial

Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial Background: There is a paucity of evidence for dose and pace of up-titration of guideline-directed medical therapies after admission to hospital for acute heart failure. Methods: In this multinational, open-label, randomised, parallel-group trial (STRONG-HF), patients aged 18-85 [...]

2023-02-22T15:32:48-04:00December 3rd, 2022|

Results of a Remotely Delivered Hypertension and Lipid Program in More Than 10 000 Patients Across a Diverse Health Care Network

Results of a Remotely Delivered Hypertension and Lipid Program in More Than 10 000 Patients Across a Diverse Health Care Network Importance  Blood pressure (BP) and cholesterol control remain challenging. Remote care can deliver more effective care outside of traditional clinician-patient settings but scaling and ensuring access to care among diverse populations remains elusive. Objective  To implement and [...]

2023-02-22T14:08:42-04:00November 9th, 2022|
Go to Top